Literature DB >> 30224242

Profiles for long non-coding RNAs in ovarian granulosa cells from women with PCOS with or without hyperandrogenism.

Li Jin1, Qian Yang2, Chengliang Zhou3, Lanxin Liu1, Huihui Wang1, Min Hou1, Yimei Wu1, Fengtao Shi1, Jianzhong Sheng4, Hefeng Huang5.   

Abstract

RESEARCH QUESTION: What is the expression pattern of long non-coding RNAs (lncRNA) in ovarian granulosa cells of women with polycystic ovary syndrome (PCOS) with or without hyperandrogenism?
DESIGN: Microarray screening of lncRNA was conducted in ovarian granulosa cells collected from women with PCOS with hyperandrogenism (PCOS-T) or without hyperandrogenism (PCOS-N) and control participants, with four samples in each group. This was followed by hierarchy clustering, gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Several candidate lncRNA were randomly selected for quantitative polymerase chain reaction validation in another 54 patients. To predict the regulatory effect of lncRNA on hyperandrogenism, a co-expression network was plotted using differentially hexpressed lncRNA with statistical significance (≥ twofold; P < 0.05) in PCOS-T compared with PCOS-N.
RESULTS: A total of 3000 and 1030 differentially expressed lncRNA (≥ twofold change) were detected in PCOS-T compared with control and PCOS-N, respectively. A total of 1361 differentially expressed lncRNA were detected in PCOS-N compared with controls. Corticotropin releasing hormone binding protein is consistently the up-regulated lncRNA with the highest fold-change in PCOS-T compared with either control or PCOS-N. Gene ontology and pathway analysis showed that dysregulated lncRNA in PCOS-T have a regulatory role in mitochondrial function by interacting with transcription factors such as YY1 and SIX5.
CONCLUSIONS: The expression patterns of lncRNA in women with PCOS were ascertained by microarray. Many lncRNA were differentially expressed in PCOS-T compared with PCOS-N, suggesting that they may play a key role in steroid genesis and metabolism.
Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hyperandrogenism; Long noncoding RNAs; Microarray; PCOS

Mesh:

Substances:

Year:  2018        PMID: 30224242     DOI: 10.1016/j.rbmo.2018.08.005

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

Review 1.  Long noncoding RNAs as a piece of polycystic ovary syndrome puzzle.

Authors:  Maryam Abolghasemi; Soleiman Mahjoub
Journal:  Mol Biol Rep       Date:  2021-05-15       Impact factor: 2.316

2.  MiR-98-3p regulates ovarian granulosa cell proliferation and apoptosis in polycystic ovary syndrome by targeting YY1.

Authors:  Min Hu; Tian Gao; Ying Du
Journal:  Med Mol Morphol       Date:  2021-11-18       Impact factor: 2.309

Review 3.  Long non-coding RNAs in ovarian granulosa cells.

Authors:  Jiajie Tu; Yu Chen; Zhe Li; Huan Yang; He Chen; Zhiying Yu
Journal:  J Ovarian Res       Date:  2020-06-05       Impact factor: 4.234

Review 4.  microRNAs and long non-coding RNAs as biomarkers for polycystic ovary syndrome.

Authors:  Mona Tamaddon; Mostafa Azimzadeh; Seyed Mohammad Tavangar
Journal:  J Cell Mol Med       Date:  2022-01-06       Impact factor: 5.310

5.  Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure.

Authors:  Qinyu Gao; Cong Ma; Shuyu Meng; Guanxiong Wang; Qiong Xing; Yuping Xu; Xiaojin He; Tianjuan Wang; Yunxia Cao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

6.  PCOS without hyperandrogenism is associated with higher plasma Trimethylamine N-oxide levels.

Authors:  Jiayu Huang; Lin Liu; Chunyan Chen; Ying Gao
Journal:  BMC Endocr Disord       Date:  2020-01-06       Impact factor: 2.763

7.  lnc-MAP3K13-7:1 Inhibits Ovarian GC Proliferation in PCOS via DNMT1 Downregulation-Mediated CDKN1A Promoter Hypomethylation.

Authors:  Xueying Geng; Jun Zhao; Jiayu Huang; Shang Li; Weiwei Chu; Wang-Sheng Wang; Zi-Jiang Chen; Yanzhi Du
Journal:  Mol Ther       Date:  2020-11-17       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.